Everything below concerns peptide analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
== Mechanism of force generation == As a result of ATP hydrolysis, filaments elongate approximately 10 times faster at their barbed ends than their pointed ends. At steady-state, the polymerization rate at the barbed end matches the depolymerization rate at the pointed end, and microfilaments are said to be treadmilling. Treadmilling results in elongation in the barbed end and shortening in the pointed-end, so that the filament in total moves. Since both processes are energetically favorable, this means force is generated, the energy ultimately coming from ATP.
==== Ciprofloxacin ==== Due to the constraints and confined environments that astronauts are exposed to for long durations of time, they are at risk for higher rates of infection. Ciprofloxacin is a common drug used to treat infections, especially bacterial of nature, and is used to study antibiotics delivery in outer space due to its good bioavailability, infrequent dose intake, multiple-dose intake abilities (oral or intravenous), and stability. This study also employs a bed-rest model called the antiorthostatis bed rest (ABR) model, where subjects lie at a 12° angle downwards to simulate space flight weightlessness. Six individuals were employed to take one dose of 250 mg ciprofloxacin, once at weightlessness and once at normal conditions, separated between fifteen days. Blood was examined at intervals of 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 8, and 12 hours and urine samples were also collected at 0, 3, 6, 8, and 12 hours after each dose. It was found that ciprofloxacin's penetration in the tissue was lower in microgravity conditions than normal, indicating tissue penetration to be an issue in outer space for ciprofloxacin. In addition, compared to doses stored at ground versus in space, there was visible discoloration in samples stored in outer space and the expiration period in outer space was much shorter than on the ground.
In general, polystyrene is not accepted in curbside collection recycling programs and is not separated and recycled where it is accepted. In Germany, polystyrene is collected as a consequence of the packaging law (Verpackungsverordnung) that requires manufacturers to take responsibility for recycling or disposing of any packaging material they sell. Most polystyrene products are currently not recycled due to the lack of incentive to invest in the compactors and logistical systems required. Due to the low density of polystyrene foam, it is not economical to collect. However, if the waste material goes through an initial compaction process, the material changes density from typically 30 kg/m3 to 330 kg/m3 and becomes a recyclable commodity of high value for producers of recycled plastic pellets. Expanded polystyrene scrap can be easily added to products such as EPS insulation sheets and other EPS materials for construction applications; many manufacturers cannot obtain sufficient scrap because of collection issues. When it is not used to make more EPS, foam scrap can be turned into products such as clothes hangers, park benches, flower pots, toys, rulers, stapler bodies, seedling containers, picture frames, and architectural molding from recycled PS. As of 2016, around 100 tonnes of EPS are recycled every month in the UK. Recycled EPS is also used in many metal casting operations. Rastra is made from EPS that is combined with cement to be used as an insulating amendment in the making of concrete foundations and walls.
=== Pseudoachondroplasia === Pseudoachondroplasia is an osteochondrodysplasia made distinctive by disproportionate short stature, hip and knee deformities, brachydactyly (short fingers) and ligamentous laxity. It affects at least 1 in 20,000 individuals. Pseudoachondroplasia is inherited in an autosomal dominant manner and is caused solely by mutations in the cartilage oligomeric matrix protein COMP gene. It's distinguished by a moderate to severe form of disproportionate short-limb short stature. The limb shortening is fundamentally confined to the proximal limb segments i.e., Femurs and humeri. A known presenting feature is a waddling gait, noticed at the onset of walking. A prompt diagnosis of a skeletal dysplasia in general and Pseudoachondroplasia in specific is still based upon a comprehensive clinical and radiographic correlation. A detailed radiographic examination of the axial and appendicular skeleton is invaluable for the differential diagnosis of Pseudoachondroplasia. Coxa vara (reduced neck shaft angle), broad femoral necks, short femurs and humeri, and bullet-shaped vertebrae are noticeable radiographic features. Additionally, the presence of metaphyseal broadening, cupping and dense line of ossification about the knee can simulate rachitic changes. These radiographic features are collectively known as rachitic-like changes. The presence of epiphyseal changes serves as an important differentiating feature from achondroplasia.
Sources: en.wikipedia.org
In the twenty-first century, donkey milk is largely used in the manufacture of soaps and moisturizers, but evidence shows it has possible medical uses to treat infants and children with cow's milk protein allergy (CMPA) as a natural "formula" for infants.
2025: Datchinamurthy Kataiah, a Malaysian drug trafficker hanged for smuggling 44.96g of diamorphine on 25 September 2025. 2025: Pannir Selvam Pranthaman, a Malaysian drug trafficker hanged on 8 October 2025 for smuggling 51.84g of diamorphine. 2026: Omar Bin Yacob Bamadhaj, a Singaporean was hanged on 16 April 2026 for trafficking 1,009.1g of cannabis in July 2018
== Places == Le Havre, a French city Lincoln Highway, in the US Locks Heath, a suburb of Fareham, UK County Louth, Ireland (code LH) L'Hospitalet de Llobregat, a city in Catalonia whose name is sometimes shortened to L'H
Sources: en.wikipedia.org
==== Copycat suicides and romanticisation ==== Another negative effect that misrepresentation of mental illnesses through the news can cause is copycat suicide. As with the deaths of celebrities Kate Spade and Robin Williams, an abundance of media and news coverage occurs. A Columbia University study revealed that "suicides rose nearly 10% higher than expected in the months following Robin Williams' death in August 2014," especially involving the method used by Robin Williams himself (a 32% increase). These results support the idea of suicide contagion, which the U.S. Department of Health & Human Services (HHS) defines as "the exposure to suicide or suicidal behaviors within one's family, one's peer group, or through media reports of suicide and can result in an increase in suicide and suicidal behaviors." A notable mid-2010s case of modern digital media contagion is the 2015 suicide of 16-year-old Russian student Renata Kambolina (known online under the pseudonym Rina Palenkova). After posting a final trackside selfie with the caption "nya. bye." ("ня.пока."), her tragic death rapidly went viral on the Russian social network VKontakte. This sparked a dangerous wave of romanticisation that falsely framed her as a virtual idol, prompting numerous vulnerable youths to replicate either her final words, her exact photo framing, or both, during their own suicides or attempted suicides—notably Gleb Korablyov in 2019. Like Kambolina, Korablyov also had his tragic death immediately seized upon and mythologised by internet trolls and morbid online communities.
== Function == Periostin is a secreted extracellular matrix protein that was originally identified in cells from the mesenchymal lineage (osteoblasts, osteoblast-derived cells, the periodontal ligament, and periosteum). It has been associated with the epithelial-mesenchymal transition in cancer and with the differentiation of mesenchyme in the developing heart. This protein shares a homology with fasciclin I, a secreted cell adhesion molecule found in insects. In many cancers, periostin binds to integrins on cancer cells, activating the Akt/PKB- and FAK-mediated signaling pathways. This leads to increased cell survival, invasion, angiogenesis, metastasis, and the epithelial-mesenchymal transition. In humans and mice, periostin undergoes alternative splicing in its C-terminal region, resulting in specific isoforms that can be observed in a broad range of cancers such as pancreatic, colon, and breast cancer. While periostin plays a wide variety of roles in tissue development along with disease, its function in tissue remodeling as a response to injury is a common underlying role in these different mechanisms. Periostin is transiently upregulated during cell fate changes, whether they are related to alterations in physiology or to pathological changes. It influences extracellular matrix restructuring, tissue remodeling, and the epithelial-mesenchymal transition, all of which can be related to tissue healing, development, and disease. Thus, it functions as a mediator, balancing appropriate and inappropriate responses to tissue damage.
NMN can be produced in the body directly from nicotinamide with the help of the enzyme nicotinamide phosphoribosyltransferase, or alternatively from nicotinamide riboside (a derivative of nicotinamide) through the application of a nicotinamide riboside kinase. In humans, there are two known forms of this enzyme: nicotinamide riboside kinase 1 (found across many tissues) and nicotinamide riboside kinase 2 (found mostly in muscles).
The SRC collapsed in 1991 with the onset of the Somali Civil War. Instability continued through periods of reduced conflict under transitional governments in the early 2000s.At the end of 2006, a US-backed Ethiopian invasion overthrew the Islamic Courts Union (ICU), leading to the installation of the Transitional Federal Government of Somalia (TFG) in Mogadishu under an Ethiopian military occupation. The subsequent insurgency which emerged saw the ICU fragment into various rebel factions, including the militant group al-Shabaab, which waged a protracted conflict against Ethiopian forces, the two powers exchanging control of territories through mid-2012. A new provisional constitution was passed in August 2012, reforming Somalia as a federation and began reconstruction under the Federal Government of Somalia. Insurgents still control much of central and southern Somalia and influence government-controlled areas. Somalia is among the least developed countries in the world because of its low GDP per capita and the Human Development Index. It has maintained an informal economy mainly based on livestock, remittances from Somalis working abroad, and telecommunications. It is a member of the United Nations, the Arab League, African Union, Non-Aligned Movement, East African Community, and the Organisation of Islamic Cooperation.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.